Cargando…

Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH...

Descripción completa

Detalles Bibliográficos
Autores principales: Shawky, Shereen, Safouh, Hesham, Gamal, Mona, Abbas, Mohammed M., Aboul-Enein, Azza, Sawai, Toshihiro, Fahmy, Yosra, Selim, Heba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616678/
https://www.ncbi.nlm.nih.gov/pubmed/34840826
http://dx.doi.org/10.1155/2021/6904858
_version_ 1784604396362924032
author Shawky, Shereen
Safouh, Hesham
Gamal, Mona
Abbas, Mohammed M.
Aboul-Enein, Azza
Sawai, Toshihiro
Fahmy, Yosra
Selim, Heba
author_facet Shawky, Shereen
Safouh, Hesham
Gamal, Mona
Abbas, Mohammed M.
Aboul-Enein, Azza
Sawai, Toshihiro
Fahmy, Yosra
Selim, Heba
author_sort Shawky, Shereen
collection PubMed
description BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH), leading to uncontrolled overactivation of the complement system. Early diagnosis and treatment of autoimmune HUS (AI-HUS) is essential and leads to a favorable outcome. METHODS: Fifty pediatric HUS patients and 50 age- and sex-matched controls were included in the study. Patients were subjected to full history taking, clinical examination, and laboratory testing. All candidates were subjected to an assessment of anti-FH in serum by a homemade enzyme-linked immunosorbent assay technique. RESULTS: A high frequency of serum anti-FH was detected in our aHUS patients. The disease onset of AI-HUS was mainly observed in March and April, with significantly higher rates in school-aged males. All patients who started immunosuppressives early together with plasmapheresis upon detection of their anti-FH had complete renal function recovery. CONCLUSION: The high frequency of AI-HUS revealed in Egyptian HUS children in our study highlights the importance of implementing anti-FH testing in Egypt to provide early recognition for immediate proper management, including early immunosuppressive therapy, and hence improving patient outcomes.
format Online
Article
Text
id pubmed-8616678
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86166782021-11-26 Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome Shawky, Shereen Safouh, Hesham Gamal, Mona Abbas, Mohammed M. Aboul-Enein, Azza Sawai, Toshihiro Fahmy, Yosra Selim, Heba Int J Nephrol Research Article BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH), leading to uncontrolled overactivation of the complement system. Early diagnosis and treatment of autoimmune HUS (AI-HUS) is essential and leads to a favorable outcome. METHODS: Fifty pediatric HUS patients and 50 age- and sex-matched controls were included in the study. Patients were subjected to full history taking, clinical examination, and laboratory testing. All candidates were subjected to an assessment of anti-FH in serum by a homemade enzyme-linked immunosorbent assay technique. RESULTS: A high frequency of serum anti-FH was detected in our aHUS patients. The disease onset of AI-HUS was mainly observed in March and April, with significantly higher rates in school-aged males. All patients who started immunosuppressives early together with plasmapheresis upon detection of their anti-FH had complete renal function recovery. CONCLUSION: The high frequency of AI-HUS revealed in Egyptian HUS children in our study highlights the importance of implementing anti-FH testing in Egypt to provide early recognition for immediate proper management, including early immunosuppressive therapy, and hence improving patient outcomes. Hindawi 2021-11-18 /pmc/articles/PMC8616678/ /pubmed/34840826 http://dx.doi.org/10.1155/2021/6904858 Text en Copyright © 2021 Shereen Shawky et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shawky, Shereen
Safouh, Hesham
Gamal, Mona
Abbas, Mohammed M.
Aboul-Enein, Azza
Sawai, Toshihiro
Fahmy, Yosra
Selim, Heba
Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title_full Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title_fullStr Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title_full_unstemmed Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title_short Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
title_sort anti-factor h antibodies in egyptian children with hemolytic uremic syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616678/
https://www.ncbi.nlm.nih.gov/pubmed/34840826
http://dx.doi.org/10.1155/2021/6904858
work_keys_str_mv AT shawkyshereen antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT safouhhesham antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT gamalmona antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT abbasmohammedm antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT abouleneinazza antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT sawaitoshihiro antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT fahmyyosra antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome
AT selimheba antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome